We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
+8.06%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$1.11T
AUM Growth
+$49.3B
Cap. Flow
-$2.91B
Cap. Flow %
-0.26%
Top 10 Hldgs %
27.74%
Holding
3,121
New
186
Increased
817
Reduced
1,825
Closed
148

Top Buys

Rank Stock Value
1
RIVN icon
Rivian
RIVN
+$18.7B
2
AAPL icon
Apple
AAPL
+$5.48B
3
NVDA icon
NVIDIA
NVDA
+$5.33B
4
TSLA icon
Tesla
TSLA
+$4.47B
5
MSFT icon
Microsoft
MSFT
+$2.15B

Top Sells

Rank Stock Value
1
V icon
Visa
V
+$4.26B
2
META icon
Meta Platforms (Facebook)
META
+$3.3B
3
MS icon
Morgan Stanley
MS
+$2.82B
4
GPN icon
Global Payments
GPN
+$2.43B
5
PYPL icon
PayPal
PYPL
+$2B

Sector Composition

Rank Sector Weight
1 Technology 27.36%
2 Healthcare 16.09%
3 Consumer Discretionary 15.79%
4 Communication Services 12.38%
5 Financials 10.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TIO
2951
DELISTED
Tingo Group, Inc. Common Stock
TIO
$20K ﹤0.01%
24,300
NAT icon
2952
Nordic American Tanker
NAT
$1.36B
$19K ﹤0.01%
11,068
-1,994
-15% -$4.28K
SONN
2953
DELISTED
Sonnet BioTherapeutics
SONN
$19K ﹤0.01%
18
CRBP icon
2954
Corbus Pharmaceuticals
CRBP
$189M
$18K ﹤0.01%
994
+47
+5% +$1.27K
CEMI
2955
DELISTED
Chembio diagnostics, Inc.
CEMI
$17K ﹤0.01%
15,200
URG
2956
Ur-Energy
URG
$537M
$15K ﹤0.01%
11,985
-3,700
-24% -$6.07K
NMTR
2957
DELISTED
9 Meters Biopharma
NMTR
$14K ﹤0.01%
716
-275
-28% -$6.15K
PRPC.WS
2958
DELISTED
CC Neuberger Principal Holdings III Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
PRPC.WS
$13K ﹤0.01%
+12,125
New +$13.7K
EUCRW
2959
DELISTED
Eucrates Biomedical Acquisition Corp. Warrant
EUCRW
$13K ﹤0.01%
22,697
TNXP icon
2960
Tonix Pharmaceuticals
TNXP
$205M
0
TRVN
2961
DELISTED
Trevena, Inc.
TRVN
$6K ﹤0.01%
16
-6
-27% -$3.32K
VELOW
2962
DELISTED
Velocity Acquisition Corp. Warrant
VELOW
$6K ﹤0.01%
+11,329
New +$6.9K
EMWP
2963
DELISTED
Eros Media World PLC
EMWP
$5K ﹤0.01%
1,122
-235
-17% -$2.69K
ABEO icon
2964
Abeona Therapeutics
ABEO
$425M
-976
Closed -$27K
ACIU icon
2965
AC Immune
ACIU
$267M
-396,919
Closed -$2.66M
ADVM
2966
DELISTED
Adverum Biotechnologies
ADVM
-5,410
Closed -$117K
AHT
2967
Ashford Hospitality Trust
AHT
$19.8M
-1,900
Closed -$280K
ALXO icon
2968
ALX Oncology
ALXO
$278M
-4,110
Closed -$304K
AQB icon
2969
AquaBounty Technologies
AQB
$7.1M
-2,032
Closed -$165K
ARCC icon
2970
Ares Capital
ARCC
$14.3B
-60,000
Closed -$1.22M
ARKO icon
2971
ARKO Corp
ARKO
$500M
-10,040
Closed -$101K
ASPS icon
2972
Altisource Portfolio Solutions
ASPS
$64.5M
-1,313
Closed -$104K
ATAI icon
2973
AtaiBeckley Inc
ATAI
$2.68B
-648,074
Closed -$9.59M
ATXS
2974
DELISTED
Astria Therapeutics
ATXS
-11,966
Closed -$106K
DCH
2975
Dauch Corp
DCH
$1.61B
-11,555
Closed -$102K

Similar funds

T. Rowe Price Associates's Q4 2021 Portfolio in Review

As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.

T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.

By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
  • T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
  • T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
  • T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
  • T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
  • T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
  • T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.

Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.